Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
FDA clears Corcept (CORT) Lifyorli combo for platinum-resistant ovarian cancer
Corcept Therapeutics announced FDA approval for its drug Lifyorli (relacorilant) in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval, based on the pivotal ROSELLA trial, demonstrated a significant 35% reduction in the risk of death and improved median overall survival by 4.1 months compared to nab-paclitaxel alone. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist for this condition, targeting a patient population of approximately 20,000 U.S. women annually, with further expansion anticipated in Europe.